WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H414297
CAS#: 11056-06-7 (free base)
Description: Bleomycin Free Base is a complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
Hodoodo Cat#: H414297
Name: Bleomycin Free Base
CAS#: 11056-06-7 (free base)
Chemical Formula: C55H84N17O21S3+
Exact Mass: 1,414.52
Molecular Weight: 1,415.550
Elemental Analysis: C, 46.67; H, 5.98; N, 16.82; O, 23.73; S, 6.79
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 9041-93-4 (sulfate) 11056-06-7 (free base)
Synonym: Bleomycin Free Base; HSDB3208; HSDB-3208; HSDB 3208; CCRIS2754; CCRIS-2754; CCRIS 2754
IUPAC/Chemical Name: (3-(2'-((3S,6R,7S,8S,11S)-1-(6-amino-2-((S)-3-amino-1-(((S)-2,3-diamino-3-oxopropyl)amino)-3-oxopropyl)-5-methylpyrimidin-4-yl)-3-((1R)-((3-((4-(carbamoyloxy)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)(1H-imidazol-4-yl)methyl)-7-hydroxy-11-((R)-1-hydroxyethyl)-6,8-dimethyl-1,4,9,12-tetraoxo-2,5,10,13-tetraazapentadecan-15-yl)-[2,4'-bithiazole]-4-carboxamido)propyl)dimethylsulfonium
InChi Key: OYVAGSVQBOHSSS-WXFSZRTFSA-O
InChi Code: InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1
SMILES Code: C[C@H]([C@@H](C(NCCc1scc(c2scc(C(NCCC[S+](C)C)=O)n2)n1)=O)NC([C@H]([C@@H]([C@H](NC([C@H]([C@H](c3nc[nH]c3)OC4OC(C(C(C4OC5OC(C(C(C5O)OC(N)=O)O)CO)O)O)CO)NC(c6c(C)c(N)nc([C@@H](NC[C@@H](C(N)=O)N)CC(N)=O)n6)=O)=O)C)O)C)=O)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 1,415.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol. 1991;65(2):81-94. doi: 10.1007/BF02034932. PMID: 1711838.
2: Lazo JS, Sebti SM. Bleomycin. Cancer Chemother Biol Response Modif. 1997;17:40-5. PMID: 9551207.
3: Lazo JS. Bleomycin. Cancer Chemother Biol Response Modif. 1999;18:39-45. PMID: 10800476.
4: Lazo JS, Sebti SM. Bleomycin. Cancer Chemother Biol Response Modif. 1994;15:44-50. PMID: 7540032.
5: Kong J, Yi L, Xiong Y, Huang Y, Yang D, Yan X, Shen B, Duan Y, Zhu X. The discovery and development of microbial bleomycin analogues. Appl Microbiol Biotechnol. 2018 Aug;102(16):6791-6798. doi: 10.1007/s00253-018-9129-8. Epub 2018 Jun 6. PMID: 29876605.
6: Lester EP, Matz GJ. Bleomycin. Otolaryngol Head Neck Surg (1979). 1979 Jul- Aug;87(4):399-400. doi: 10.1177/019459987908700401. PMID: 92001.
7: Saitta P, Krishnamurthy K, Brown LH. Bleomycin in dermatology: a review of intralesional applications. Dermatol Surg. 2008 Oct;34(10):1299-313. doi: 10.1111/j.1524-4725.2008.34281.x. Epub 2008 Jun 27. PMID: 18616538.
8: Chen H, Cui J, Wang P, Wang X, Wen J. Enhancement of bleomycin production in Streptomyces verticillus through global metabolic regulation of N-acetylglucosamine and assisted metabolic profiling analysis. Microb Cell Fact. 2020 Feb 13;19(1):32. doi: 10.1186/s12934-020-01301-8. PMID: 32054531; PMCID: PMC7017467.
9: Povirk LF, Austin MJ. Genotoxicity of bleomycin. Mutat Res. 1991 Mar;257(2):127-43. doi: 10.1016/0165-1110(91)90022-n. PMID: 1706477.
10: Douglas KT, Ratwatte HA, Thakrar N. Photoreactivity of bleomycin and its implications. Bull Cancer. 1983;70(5):372-80. PMID: 6199058.
